Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring its push to scale in the world’s largest generics market.
In March, Senores signed a pact to buy 14 ANDAs from http://Dr. Reddy’s LaboratoriesDr. Reddy’s Laboratories. In July, the board raised the company’s stake in US-based Havix to about 73% to deepen local manufacturing and supply. The latest Teva transaction will draw on IPO proceeds, staying in line with the company’s red herring prospectus, the management said.
Why this deal matters
ANDAs give faster entry into priority molecules. With Havix capacity in the US, Senores can file, launch, and service buyers with shorter lead times. That matters as buyers seek dependable supply and sharper pricing.
Strategy and outlook
Managing Director Swapnil Shah said the US market contributes roughly 70% of revenue. “We make products locally for the US, which gives us a cushion against policy swings,” he noted. Shah added that Senores will pursue more acquisitions, but only when the assets fit its plan and add scale in core therapies.
The bigger picture
US pricing stays tough, and tariff chatter lingers. Even so, Senores is stacking assets: a larger basket of ANDAs, higher US capacity, and a war chest from the IPO. Together, these moves aim to speed launches, lift service levels, and protect margins.
https://medicarepharmabusiness.com/pharma
